CellPress is showcasing a collection of CTD² Network’s articles which will help develop precision therapeutics in cancer. Register for the Cell-NCI Symposium: Beyond Cancer Genomics Toward Precision Oncology taking place from October 4-6, 2021.
Glioblastoma is both the most common and lethal primary malignant brain tumor.
The fusion of empirical science with large-scale computing platforms has allowed rapid advances in our ability to model physiological and pathophysiological processes in silico.
A comprehensive understanding of the molecular vulnerabilities of every type of cancer will provide a powerful roadmap to guide therapeutic approaches.
The authors introduce a small molecule to induce apoptosis selectively in cancer cells.
High-throughput tools for nucleic acid characterization now provide the means to conduct comprehensive analyses of all somatic alterations in the cancer genomes.
The authors screened 124 genes that are amplified in human hepatocellular carcinoma (HCC) using a mouse hepatoblast model and identified 18 tumor-promoting genes, including CCND1 and its neighbor on 11q13.3, FGF19.
Genomic analysis of primary tumors is providing extraordinary insights into the molecular changes in genes and pathways that cause cancer.
Researchers discover that two transcription factors C/EBPbeta and STAT3 are responsible for mesenchymal transformation in glioma.